10.6084/m9.figshare.c.3871963_D1.v1
Faye Norby
Faye
Norby
Lindsay Bengtson
Lindsay
Bengtson
Pamela Lutsey
Pamela
Lutsey
Lin Chen
Lin
Chen
Richard MacLehose
Richard
MacLehose
Alanna Chamberlain
Alanna
Chamberlain
Ian Rapson
Ian
Rapson
Alvaro Alonso
Alvaro
Alonso
Additional file 1: Supplemental Materials. of Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Springer Nature
2017
Non-valvular atrial fibrillation
Stroke
Warfarin
Dabigatran
Rivaroxaban
2017-09-06 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Supplemental_Materials_of_Comparative_effectiveness_of_rivaroxaban_versus_warfarin_or_dabigatran_for_the_treatment_of_patients_with_non-valvular_atrial_fibrillation/5378707
Table S1. Characteristics of atrial fibrillation patients by anticoagulant use prior to final matching based on high-dimensional propensity score, MarketScan, 2010–2014. Table S2. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users (categorized by initial dose) to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S3. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing patients who switched to rivaroxaban (categorized by initial dose) from warfarin to warfarin-only users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S4. Adjusted hazard ratios (95% confidence intervals) comparing new rivaroxaban users (categorized by initial dose) to new dabigatran users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S5. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Restricted to 36,623 patients with at least 180 days of enrolment before first oral anticoagulation prescription. Table S6. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Restricted to 68,927 patients with an enrolment date later than January 1st, 2011. Table S7. ICD-9-CM codes for outcomes. Table S8. ICD-9-CM codes used to define comorbidities. Figure S1. High-dimensional propensity score distribution by oral anticoagulant status for the outcome of stroke. These are the distributions prior to final matching based on high-dimensional propensity score. (DOCX 356 kb)